Strength
45 mg/1
Manufacturer
AbbVie Inc.NDC
00074104328
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Last Updated
1/2/2026
Active Ingredients
UPADACITINIBApproval Type
New Drug (NDA)
FDA Application
NDA211675On Market Since
8/16/2019
Pharmacological Classes
Janus Kinase Inhibitor
Janus Kinase Inhibitors
Generic Alternatives
No alternatives available
No alternatives found with the same active ingredient, strength, and dosage form.
Related Drugs
Same classification
OPZELURA 1.5% CREAM
Brand
50881000705•Incyte Corporation
$34.1433
per GM
XELJANZ 5 MG TABLET
Brand
00069100101•Pfizer Inc.
$73.8329
per EA
OLUMIANT 2 MG TABLET
Brand
00002418230•Eli Lilly and Company
$92.2936
per EA
XELJANZ 10 MG TABLET
Brand
00069100201•Pfizer Inc.
$103.5456
per EA
OLUMIANT 4 MG TABLET
Brand
00002447930•Eli Lilly and Company
$184.6623
per EA
CIBINQO 100 MG TABLET
Brand
00069033530•Pfizer Inc.
$197.1952
per EA
XELJANZ XR 11 MG TABLET
Brand
00069050130•Pfizer Inc.
$207.7104
per EA